€57,48 €47,50 excl. VAT
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle elicited upon exposure to inhalation anesthetics and depolarizing muscle relaxants.
10 working days
From €5,95 shipping and administration per order (incl. VAT)
Specifications
| Breeds | |
|---|---|
| Gene | |
| Organ | |
| specimen | Swab, Blood EDTA, Blood Heparin, Semen, Tissue |
| Mode of Inheritance | |
| Chromosome | |
| Also known as | |
| Year Published |
General information
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle elicited upon exposure to inhalation anesthetics and depolarizing muscle relaxants. It is considered to be a clinical syndrome rather than a single disease because multiple environmental and genetic factors cause a complex of events. MH has also been reported in humans, pigs, cats and horses.
Clinical features
MH-susceptible (MHS) dogs show no clinical signs until exposed to inhalation anesthetics and depolarizing muscle relaxants. When exposed, MHS dogs show tachycardia, hyperthermia, elevated CO2 levels and eventually death if the used anesthetic is not discontinued.
Additional information
References
Pubmed ID: 11575546, 15474681
Omia ID: 621